Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medeva single isomer methylphenidate NDA expected in 1999; Apothecon licenses Medeva generic.

Executive Summary

MEDEVA/CHIROSCIENCE SINGLE ISOMER METHYLPHENIDATE NDA EXPECTED IN 1999 as part of simultaneous filings in the U.S. and Europe, Medeva told a recent meeting with securities analysts in London. Medeva and Chiroscience completed Phase I studies of the d-threo isomer of the attention deficit/hyperactivity disorder therapy methylphenidate in 1996. The companies believe the single isomer compound could have "reduced dosing and linear pharmacokinetics" compared to the racemic compound, which has "short-acting characteristics and non-linear pharmacokinetics, which make dosing and dose titration less easy and predictable," Medeva said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029768

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel